drugset
drugset / Trial / NCT04540393

AZD1222 Vaccine for the Prevention of COVID-19

NCT04540393 ↗

Phase 3 Withdrawn AstraZeneca Covance · collabIQVIA Pty Ltd · collab
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate safety and immunogenicity of AZD1222 for COVID-19 prevention in the Russian Federation

Timeline

Start
2020-09-02
Primary completion
2020-12-04
Completion
2022-05-11

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1222 Vaccine 5e+10 unknown Intramuscular

Indications

COVID-19